NASDAQ:IKNA Ikena Oncology (IKNA) Stock Price, News & Analysis $1.67 +0.12 (+7.74%) (As of 12/23/2024 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Ikena Oncology Stock (NASDAQ:IKNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ikena Oncology alerts:Sign Up Key Stats Today's Range$1.63▼$1.9450-Day Range$1.55▼$1.7652-Week Range$1.22▼$2.29Volume5.14 million shsAverage Volume250,165 shsMarket Capitalization$80.59 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingModerate Buy Company OverviewIkena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More… Ikena Oncology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreIKNA MarketRank™: Ikena Oncology scored higher than 52% of companies evaluated by MarketBeat, and ranked 676th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingIkena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIkena Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Ikena Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ikena Oncology are expected to grow in the coming year, from ($0.91) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ikena Oncology is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ikena Oncology is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIkena Oncology has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.33% of the float of Ikena Oncology has been sold short.Short Interest Ratio / Days to CoverIkena Oncology has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ikena Oncology has recently increased by 9.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIkena Oncology does not currently pay a dividend.Dividend GrowthIkena Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.33% of the float of Ikena Oncology has been sold short.Short Interest Ratio / Days to CoverIkena Oncology has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ikena Oncology has recently increased by 9.69%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.21 News SentimentIkena Oncology has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ikena Oncology this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ikena Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.94% of the stock of Ikena Oncology is held by insiders.Percentage Held by Institutions75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ikena Oncology's insider trading history. Receive IKNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address IKNA Stock News HeadlinesiKena Oncology, Inmagene enter definitive merger agreement, private placementDecember 24 at 4:42 AM | markets.businessinsider.comIkena Oncology Shares Rise After Merger Announcement With Inmagene BiopharmaceuticalsDecember 23 at 4:20 PM | marketwatch.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 24, 2024 | Brownstone Research (Ad)Ikena Oncology, Inmagene Biopharmaceuticals to MergeDecember 23 at 11:19 AM | marketwatch.comIkena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementDecember 23 at 8:37 AM | globenewswire.comIkena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementDecember 23 at 8:30 AM | globenewswire.comBuy Rating for Ikena Oncology Driven by Promising IK-595 DevelopmentsNovember 11, 2024 | markets.businessinsider.comIkena Oncology Reports Strategic Realignment and Financial PerformanceNovember 8, 2024 | markets.businessinsider.comSee More Headlines IKNA Stock Analysis - Frequently Asked Questions How have IKNA shares performed this year? Ikena Oncology's stock was trading at $1.97 at the beginning of the year. Since then, IKNA stock has decreased by 15.2% and is now trading at $1.67. View the best growth stocks for 2024 here. How were Ikena Oncology's earnings last quarter? Ikena Oncology, Inc. (NASDAQ:IKNA) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08. When did Ikena Oncology IPO? Ikena Oncology (IKNA) raised $125 million in an IPO on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO. Who are Ikena Oncology's major shareholders? Ikena Oncology's top institutional investors include BML Capital Management LLC (1.50%), NEA Management Company LLC (1.24%), Jacobs Levy Equity Management Inc. (0.81%) and Geode Capital Management LLC (0.56%). View institutional ownership trends. How do I buy shares of Ikena Oncology? Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ikena Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ikena Oncology investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings11/07/2024Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IKNA CUSIPN/A CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+79.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,170,000.00 Net MarginsN/A Pretax Margin-9,067.17% Return on Equity-36.88% Return on Assets-33.08% Debt Debt-to-Equity RatioN/A Current Ratio15.32 Quick Ratio15.32 Sales & Book Value Annual Sales$659,000.00 Price / Sales122.29 Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book0.47Miscellaneous Outstanding Shares48,258,000Free Float45,391,000Market Cap$80.59 million OptionableNot Optionable Beta0.49 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IKNA) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.